ImmunoVaccine (IMV) Trading 3.5% Higher After Insider Buying Activity

ImmunoVaccine Inc. (TSE:IMV) traded up 3.5% during mid-day trading on Monday following insider buying activity. The company traded as high as C$2.06 and last traded at C$2.05. 119,697 shares traded hands during trading, a decline of 28% from the average session volume of 167,025 shares. The stock had previously closed at C$1.98.

Specifically, Director Alfred Smithers bought 33,600 shares of the company’s stock in a transaction on Wednesday, January 24th. The shares were bought at an average cost of C$2.09 per share, for a total transaction of C$70,224.00.

The company has a market cap of $260.51, a price-to-earnings ratio of -22.56 and a beta of 0.53.

COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/29/immunovaccine-imv-trading-3-5-higher-after-insider-buying-activity.html.

ImmunoVaccine Company Profile

Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

Receive News & Ratings for ImmunoVaccine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply